他の有機化合物及び無機化合物含有医薬技術 (JP Patent Analysis Report)
The Theme Code "他の有機化合物及び無機化合物含有医薬技術" had 170 patent application filings in the most recent period (2023-01-01 to 2023-03-31). This is a significantly decreased of -1,073 filings (-86.3%) over 1,243 they had in the same period of the previous year (2022-01-01 to 2022-03-31).
The highest number of filings in 2017 with 7,865 cases, and their lowest number in 2022 with 5,052 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 32,186 cases in total) is 5,364, and the median is 5,936. The coefficient of variation (standard deviation/mean) is 0.4, and there have been big fluctuations in the number of filings from year to year.
| Index | Value |
|---|---|
| Average | 5,364 patents |
| Std Dev | 2,348 |
| COV | 0.4 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 5,052 cases | -11.94 % |
| 2021 year | 5,737 cases | -6.49 % |
| 2020 year | 6,135 cases | -15.81 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 他の有機化合物及び無機化合物含有医薬技術[4C086] for the period of the last 10 years (2014-01-01 to 2024-11-30). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 他の有機化合物及び無機化合物含有医薬技術, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
- Table of Contents
- Foreign Patent Analysis Report
- Patent Filing Summary for 他の有機化合物及び無機化合物含有医薬技術
- Search Set (Search Formula/Analysis Patents)
- Related Patent Analysis Report
- Competitors Information
- Top company Information
- • Information on Important Patents
- Provision of patent information to the media
- About this Site
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
Introduction
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
他の有機化合物及び無機化合物含有医薬技術, Changes in the Number of JP Patents/Patent Applications
The changes in the number of patent filings of 他の有機化合物及び無機化合物含有医薬技術 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
Patent Landscape ({{ld.d.db_name | country_map: 'en'}})
Patent landscaping is a visualization of the distribution of patent filings (application focus areas) for each technical keyword. Mountains and islands indicated by heatmap contours represent clusters of patent applications filed, and red areas on the heatmap indicate many patent filings relating to the keyword.
The patent landscape for 他の有機化合物及び無機化合物含有医薬技術 gives an intuitive understanding of what patent filings they have made and what technical position is to be established. By selecting filing year checkboxes and filtering, you can track their past filing trends (what technical area they have focused on).
By selecting applicant/patent holder checkboxes and filtering, you can visually grasp the technical areas of the filings for each applicant and the partnerships or alliances formed. Please use it as a guide for patent analysis and IP landscaping.
In addition, by visually representing the patent data in this manner, you can convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
In Patent Integration, you can check the specifics of a patent filing by clicking anywhere on the patent landscape screen. You can also quickly check the position of each applicant for each technical field by cross-referencing with other keywords and patent classifications. You can use it as a guide when considering hypotheses about each company's IP strategy on the IP Landscape. You can also use it for higher-grade intellectual property activities. It has reasonable pricing and a simple user interface that is easy for beginners to handle.
Characteristic Terms (Importance)
The following is a list of words (characteristic terms) often used in 他の有機化合物及び無機化合物含有医薬技術 patent applications. Characteristic terms with a higher importance are used in more patents/patent applications.
Search Set (Analysis Patents)
This patent analysis report was created for a patent search set of 62,225 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
他の有機化合物及び無機化合物含有医薬技術[4C086]
Same industry / competition company information (JP)
The patent information of the higher applicant in the technical theme 他の有機化合物及び無機化合物含有医薬技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
Comparing the number of applications of each company, ノバルティスアーゲー has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 48 cases, followed by エフホフマン-ラロシュアーゲー with 48 cases.
| Name | Cases |
|---|---|
| ノバルティスアーゲー | 48 cases |
| エフホフマン-ラロシュアーゲー | 48 cases |
| ブリストル-マイヤーズスクイブカンパニー | 32 cases |
| ヤンセンファーマシューティカエヌベー | 32 cases |
| 大正製薬株式会社 | 27 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 25 cases |
| アストラゼネカ・アクチエボラーグ | 21 cases |
| 武田薬品工業株式会社 | 12 cases |
| アステラス製薬株式会社 | 9 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
Comparing the number of applications of each company, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 875 cases, followed by エフホフマン-ラロシュアーゲー with 623 cases.
| Name | Cases |
|---|---|
| ノバルティスアーゲー | 875 cases |
| エフホフマン-ラロシュアーゲー | 623 cases |
| ブリストル-マイヤーズスクイブカンパニー | 481 cases |
| ヤンセンファーマシューティカエヌベー | 373 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 361 cases |
| 武田薬品工業株式会社 | 343 cases |
| 大正製薬株式会社 | 238 cases |
| アストラゼネカ・アクチエボラーグ | 188 cases |
| メルク・シャープ・アンド・ドーム・コーポレーション | 144 cases |
| アステラス製薬株式会社 | 89 cases |
| メルク・シャープ・エンド・ドーム・コーポレイション | 2 cases |
Same industry / competition company, Change in the Number of JP Patents
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
Top company information (JP)
The patent information of the higher applicant in the technical theme 他の有機化合物及び無機化合物含有医薬技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
among the top coapplicants, ノバルティスアーゲー has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 48 cases, followed by エフホフマン-ラロシュアーゲー with 48 cases.
| Name | Cases |
|---|---|
| ノバルティスアーゲー | 48 cases |
| エフホフマン-ラロシュアーゲー | 48 cases |
| 大正製薬株式会社 | 27 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 25 cases |
| 武田薬品工業株式会社 | 12 cases |
| アステラス製薬株式会社 | 9 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
among the top coapplicants, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 875 cases, followed by エフホフマン-ラロシュアーゲー with 623 cases.
| Name | Cases |
|---|---|
| ノバルティスアーゲー | 875 cases |
| エフホフマン-ラロシュアーゲー | 623 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 361 cases |
| 武田薬品工業株式会社 | 343 cases |
| 大正製薬株式会社 | 238 cases |
| アステラス製薬株式会社 | 89 cases |
| メルク・シャープ・エンド・ドーム・コーポレイション | 2 cases |
Top company, Change in the Number of JP Patents
Below is a ranking of the number of JP patent applications by 他の有機化合物及び無機化合物含有医薬技術’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by 他の有機化合物及び無機化合物含有医薬技術’s top 7 coapplicants over the last 20 years.
Top company Details (JP)
Trends in filing of joint patent applications with ノバルティスアーゲー
他の有機化合物及び無機化合物含有医薬技術 filed 875 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 392 cases in total) is 65.3, and the median is 67.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2014 with 144 cases, and their lowest number in 2022 with 46 cases.
| Index | Value |
|---|---|
| Average | 65.3 patents |
| Std Dev | 36.7 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 46 cases | -11.54 % |
| 2021 year | 52 cases | -37.3 % |
| 2020 year | 83 cases | -13.54 % |
Trends in filing of joint patent applications with 武田薬品工業株式会社
他の有機化合物及び無機化合物含有医薬技術 filed 343 joint applications with 武田薬品工業株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 153 cases in total) is 25.5, and the median is 22.0. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 56 cases, and their lowest number in 2022 with 11 cases.
| Index | Value |
|---|---|
| Average | 25.5 patents |
| Std Dev | 18.1 |
| COV | 0.7 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 11 cases | -35.3 % |
| 2021 year | 17 cases | -37.0 % |
| 2020 year | 27 cases | -40.0 % |
Trends in filing of joint patent applications with エフホフマン-ラロシュアーゲー
他の有機化合物及び無機化合物含有医薬技術 filed 623 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 293 cases in total) is 48.8, and the median is 53.5. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2014 with 97 cases, and their lowest number in 2022 with 47 cases.
| Index | Value |
|---|---|
| Average | 48.8 patents |
| Std Dev | 23.0 |
| COV | 0.5 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 47 cases | -11.32 % |
| 2021 year | 53 cases | -1.85 % |
| 2020 year | 54 cases | -25.00 % |
Trends in filing of joint patent applications with 大正製薬株式会社
他の有機化合物及び無機化合物含有医薬技術 filed 238 joint applications with 大正製薬株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 97 cases in total) is 16.2, and the median is 17.0. The coefficient of variation (standard deviation/mean) is 0.4, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2017 with 42 cases, and their lowest number in 2019 with 11 cases.
| Index | Value |
|---|---|
| Average | 16.2 patents |
| Std Dev | 6.8 |
| COV | 0.4 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 18 cases | -35.7 % |
| 2021 year | 28 cases | +55.6 % |
| 2020 year | 18 cases | +63.6 % |
Trends in filing of joint patent applications with ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング
他の有機化合物及び無機化合物含有医薬技術 filed 361 joint applications with ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 156 cases in total) is 26.0, and the median is 29.0. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2014 with 71 cases, and their lowest number in 2020 with 20 cases.
| Index | Value |
|---|---|
| Average | 26.0 patents |
| Std Dev | 13.5 |
| COV | 0.5 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 25 cases | -35.9 % |
| 2021 year | 39 cases | +95.0 % |
| 2020 year | 20 cases | -48.7 % |
Information on important patents (JP)
The following shows JP patents held by 他の有機化合物及び無機化合物含有医薬技術 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 他の有機化合物及び無機化合物含有医薬技術’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 他の有機化合物及び無機化合物含有医薬技術 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
Glossary
- Cited
- Indicates that the patent/patent application has been cited (by Examiners) in notices of reasons for rejection in the examination process of other (Japanese, U.S., or European) patent applications. The higher the number of citations, the more important the patent/patent application is considered to be.
- Request for invalidation trial
- Indicates that a third party has requested a procedure to invalidate the patent. It is likely to affect the business of third parties and is considered to be of high importance.
- Opposition
- Indicates that a third party has filed a petition with the Patent Office to hear the validity of the patent again. Like the trial for invalidation, it is considered to be of high importance.
- Information provision
- Indicates that a third party has provided the Patent Office with useful information for examination for the patent filed. It is usually considered to be of high importance because it is done to prevent the patent from being granted.
- Browsing request
- Indicates that a third party has requested the Patent Office to view the patent bag (a set of documents exchanged between the Patent Office and the applicant). The bag is often checked prior to trial for invalidation, opposition, and provision of information, and is considered to be a highly important patent.
Invalidationed Trial cases
List of latest Invalidationed Trial patents
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 44 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.5 times. The most recently Invalidation Trial patent is 特許4001199 "ヒドロピリジン誘導体酸付加塩" (Invalidation Trial day 2024-10-10) , next is 特許4029974 "ヒドロピリジン誘導体酸付加塩を含有する医薬" (Invalidation Trial day 2024-09-20) .
| - | No. | Title | Invalidation Trial days |
|---|---|---|---|
| 1 | 特許4001199 | ヒドロピリジン誘導体酸付加塩 | 2024-10-10 |
| 2 | 特許4029974 | ヒドロピリジン誘導体酸付加塩を含有する医薬 | 2024-09-20 |
| 3 | 特許5849947 | 放出制御医薬組成物 | 2024-09-17 |
| 4 | 特許6995822 | ＤＰＰ ＩＶインヒビターの使用 | 2024-06-25 |
| 5 | 特許7174020 | 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療 | 2024-05-31 |
| 6 | 特許5419866 | 新たな医薬組成物 | 2024-05-30 |
| 7 | 特許6144713 | 新たな医薬組成物 | 2024-05-30 |
| 8 | 特許5735078 | 新たな医薬組成物 | 2024-05-30 |
| 9 | 特許6560289 | 新たな医薬組成物 | 2024-05-30 |
| 10 | 特許6814997 | ５’キャップ付ＲＮＡを合成するための組成物および方法 | 2024-05-15 |
Top Patents/Patent Applications with the Highest Number of Invalidationed Trial
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 25 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.3. The most invalidation trial patent is 特許6445123 "癌を治療するための方法及び組成物" (5 times) , and the next most invalidation trial patent is 特許5906333 "プロタンパク質コンベルターゼスブチリシンケクシン９型（ＰＣＳＫ９）に対する抗原結合タンパク質" (2 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許6445123 | 癌を治療するための方法及び組成物 | 5 times |
| 2 | 特許5906333 | プロタンパク質コンベルターゼスブチリシンケクシン９型（ＰＣＳＫ９）に対する抗原結合タンパク質 | 2 times |
| 3 | 特許6198346 | １回当たり１００〜２００単位のＰＴＨが週１回投与されることを特徴とする、ＰＴＨ含有骨粗鬆症治療／予防剤 | 2 times |
| 4 | 特許6480887 | メトホルミン治療に不適切な患者における糖尿病の治療 | 2 times |
| 5 | 特許6143809 | ＤＰＰＩＶインヒビターの使用 | 2 times |
Oppositioned cases
List of latest Oppositioned patents
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 49 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7444375 "下部尿路症状改善用組成物" (Opposition day 2024-09-04) , next is 特許7446003 "マカ抽出物及びその用途" (Opposition day 2024-09-04) .
| - | No. | Title | Opposition days |
|---|---|---|---|
| 1 | 特許7444375 | 下部尿路症状改善用組成物 | 2024-09-04 |
| 2 | 特許7446003 | マカ抽出物及びその用途 | 2024-09-04 |
| 3 | 特許7425603 | 医薬組成物 | 2024-07-29 |
| 4 | 特許7425560 | 固形製剤の製造方法 | 2024-07-22 |
| 5 | 特許7512762 | スガマデクス含有の液体製剤 | 2024-07-11 |
| 6 | 特許7402687 | 医薬組成物 | 2024-06-21 |
| 7 | 特許7391858 | ポリ硫酸化多糖類を用いた術後関節痛の処置 | 2024-05-24 |
| 8 | 特許7366515 | 外用組成物 | 2024-04-23 |
| 9 | 特許7376250 | 皮膚外用組成物 | 2024-04-20 |
| 10 | 特許7364497 | 緑茶抽出物含有組成物、機能性食品 | 2024-04-18 |
Protested cases
List of latest Protested patents
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 305 patents Protest from third parties. The average number of Protest is 1.9 times. The most recently Protest patent is 特開2024-096506 "外用製剤" (Protest day 2024-11-12) , next is 特開2022-183421 "プロスタグランジンＥ２産生抑制皮膚外用剤" (Protest day 2024-11-07) .
| - | No. | Title | Protest days |
|---|---|---|---|
| 1 | 特開2024-096506 | 外用製剤 | 2024-11-12 |
| 2 | 特開2022-183421 | プロスタグランジンＥ２産生抑制皮膚外用剤 | 2024-11-07 |
| 3 | 特表2024-501951 | 小胞体ストレス減少用組成物 | 2024-11-05 |
| 4 | 特開2021-059525 | 水中油型乳化組成物、及び水中油型乳化組成物の液だれ抑制方法 | 2024-10-31 |
| 5 | 特開2022-070845 | 浸透促進方法 | 2024-10-30 |
| 6 | 特開2020-066592 | 水性貼付剤 | 2024-10-30 |
| 7 | 特開2022-076151 | 変色が抑制された経口組成物及びその変色抑制方法 | 2024-10-25 |
| 8 | 特開2022-100719 | 認知機能における作業記憶向上用組成物 | 2024-10-17 |
| 9 | 特許7037667 | ＳＴＩＮＧアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド | 2024-10-09 |
| 10 | 特表2023-542536 | オリゴ糖組成物及び使用方法 | 2024-10-09 |
| 11 | 特開2021-046394 | ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物 | 2024-10-09 |
| 12 | 特開2021-059524 | 外用組成物、及び外用組成物におけるヘパリン類似物質の安定化方法 | 2024-10-04 |
| 13 | 特開2022-021943 | 外用組成物、マスク製剤 | 2024-10-03 |
| 14 | 特開2021-052742 | 難水溶性物質含有製剤 | 2024-10-02 |
| 15 | 特開2023-085454 | 低濃度アトロピン眼科用製剤の安定性を改善するための方法 | 2024-10-01 |
| 16 | 特開2024-091928 | 安定なアジルサルタン微細結晶の製造方法 | 2024-09-30 |
| 17 | 特開2024-040421 | 水性液剤 | 2024-09-30 |
| 18 | 特表2023-514396 | 抗菌組成物 | 2024-09-27 |
| 19 | 特開2021-011469 | 新規軟膏剤 | 2024-09-20 |
| 20 | 特開2020-200317 | 大気有害物質の付着抑制方法 | 2024-09-19 |
Top Patents/Patent Applications with the Highest Number of Protested
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 628 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.7. The most protest patent is 特開2020-193227 "外用組成物" (13 times) , and the next most protest patent is 特許7320919 "小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療" (10 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特開2020-193227 | 外用組成物 | 13 times |
| 2 | 特許7320919 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 | 10 times |
| 3 | 特開2018-048105 | 外用組成物 | 10 times |
| 4 | 特開2018-048104 | 外用組成物 | 9 times |
| 5 | 特許7578941 | 経口ゲル状組成物 | 8 times |
Inspectioned cases
List of latest Inspectioned patents
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 1,147 patents Inspection from third parties. The average number of Inspection is 2.1 times. The most recently Inspection patent is 特表2022-547154 "調節可能な制御のためのＣＡ２－ＩＬ１５融合タンパク質" (Inspection day 2024-11-25) , next is 特表2022-516318 "カプセル化ポリヌクレオチド及び使用方法" (Inspection day 2024-11-22) .
| - | No. | Title | Inspection days |
|---|---|---|---|
| 1 | 特表2022-547154 | 調節可能な制御のためのＣＡ２－ＩＬ１５融合タンパク質 | 2024-11-25 |
| 2 | 特表2022-516318 | カプセル化ポリヌクレオチド及び使用方法 | 2024-11-22 |
| 3 | 特表2022-514116 | 新規な癌抗原及び方法 | 2024-11-21 |
| 4 | 特開2023-093545 | ＰＳＭＡ標的化ガンイメージングまたは放射線療法中の健康組織保護のための２－ＰＭＰＡのプロドラッグ | 2024-11-20 |
| 5 | 特表2021-530478 | ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物 | 2024-11-18 |
| 6 | 特許7194240 | 抗ＢＣＭＡ抗体、ＢＣＭＡ及びＣＤ３に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
| 7 | 特開2023-027228 | 抗ＢＣＭＡ抗体、ＢＣＭＡ及びＣＤ３に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
| 8 | 特表2018-525005 | 抗ＢＣＭＡ抗体、ＢＣＭＡ及びＣＤ３に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
| 9 | 特開2022-097486 | ｍＲＮＡの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 | 2024-11-14 |
| 10 | 特開2022-100719 | 認知機能における作業記憶向上用組成物 | 2024-11-13 |
| 11 | 特開2022-140622 | 器官の生存率を改善する方法 | 2024-11-13 |
| 12 | 特開2022-159381 | 化合物 | 2024-11-12 |
| 13 | 特表2024-501951 | 小胞体ストレス減少用組成物 | 2024-11-12 |
| 14 | 特開2022-183421 | プロスタグランジンＥ２産生抑制皮膚外用剤 | 2024-11-11 |
| 15 | 特開2023-060159 | 外用組成物 | 2024-11-08 |
| 16 | 特許5208113 | 特定のエンドセリン受容体アンタゴニストとＰＤＥ５阻害剤を含む治療用組成物 | 2024-11-08 |
| 17 | 特開2022-137094 | グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法 | 2024-11-07 |
| 18 | 特表2023-535067 | ヒトにおける呼吸器疾患の治療及び／又は予防のためのβ－ヒドロキシブチレート及び関連化合物の投与 | 2024-11-07 |
| 19 | 特表2022-545835 | 甲状腺眼症の治療方法 | 2024-11-07 |
| 20 | 特表2023-504773 | 眼遺伝子送達のためのＡＡＶベクター変異体 | 2024-11-07 |
Top Patents/Patent Applications with the Highest Number of Inspectioned
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 2,077 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.7. The most inspection patent is 特開2017-149726 "Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療" (46 times) , and the next most inspection patent is 特開2017-214435 "抗ＣＤ２０抗体の投与を含むＢ細胞リンパ腫の併用療法" (43 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特開2017-149726 | Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療 | 46 times |
| 2 | 特開2017-214435 | 抗ＣＤ２０抗体の投与を含むＢ細胞リンパ腫の併用療法 | 43 times |
| 3 | 特開2018-048105 | 外用組成物 | 32 times |
| 4 | 特許6142892 | 経口投与用医薬組成物 | 30 times |
| 5 | 特許7376250 | 皮膚外用組成物 | 30 times |
Cited cases
Top Patents/Patent Applications with the Highest Number of Cited
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 8,717 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.1. The most cited patent is 特許6833218 "非血管狭窄のための薬物コーティングされたバルーンカテーテル" (36 times) , and the next most cited patent is 特許6785819 "ＫＲＡＳ Ｇ１２Ｃ阻害剤及びその使用方法" (34 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許6833218 | 非血管狭窄のための薬物コーティングされたバルーンカテーテル | 36 times |
| 2 | 特許6785819 | ＫＲＡＳ Ｇ１２Ｃ阻害剤及びその使用方法 | 34 times |
| 3 | 特許6778114 | イミド系タンパク質分解モジュレーター及び関連する使用方法 | 34 times |
| 4 | 特許7078274 | ナノ構造体をコーティングするための化学化合物 | 33 times |
| 5 | 特開2017-104848 | シリコン微細ナノ粒子及び／又はその凝集体及び生体用水素発生材及びその製造方法並びに水素水とその製造方法及び製造装置 | 32 times |
Providing patent information to the media (newspapers, magazines, etc.)
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
About this Site
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
Please note the following points for use.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
Citation of patent application status and ranking information
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Graphs are image data.
Please note that the various graphs are image data, but we cannot provide them in text data.Scope of coverage for each goal/target
- Based on the description of each goal and target of the SDGs, we have set the scope of technologies to be covered based on our and e-Patent's past experience, etc. (in some cases, the search is based on social issues themselves). Therefore, please note that there is a possibility that this "SDGs Global Company Ranking from Patent Perspective" may not cover 100%.
- A population search formula is clearly indicated for each goal/target (database: Patent Integration). You may use the population search formula as it is, or you may improve it by yourself.
- This search covers patents and utility models, including both published and registered patents (design and design patents are excluded). The unit of count is the number of applications, not the number of patent families.
About the name collation and name control of applicants and right holders
- Company rankings are based on the results calculated by "Patent Integration", with Japanese organizations in Japanese and other companies in English (some are in Japanese).
- Company names may be the names of the companies at the time of application, but the results calculated by Patent Integration are used as is. Company names are used as they were at the time of application.
- Because of the fluctuation in the names of companies (i.e., applicant/right holder names in the patent information), there are cases where the same company appears more than once in the top 10. The number of applications filed by the same company in the top 10 is the total number of applications filed by the company.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International
Our Commitment to Safety and Security
Patent Integration Co., Ltd. is committed to providing high-quality patent information based on the latest patent data on more than 45 million cases collected from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publication. 
Patent Integration Co., Ltd. collects the patent data from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publications to provide it widely in the form of reports so that anyone can check patent information and patent trends with confidence. 
Patent Integration Co., Ltd. is committed to various efforts to enhance the reliability of the information and to allow users to search patent information with confidence.